FAQ: GeoVax Labs $2.5 Million Registered Direct Offering
Summary
GeoVax Labs announced a $2.5 million registered direct offering to institutional investors, with proceeds intended to advance the company's product candidates including COVID-19 vaccines and cancer therapies through research, development, manufacturing, and clinical studies.
What is the main announcement from GeoVax Labs?
GeoVax Labs announced a $2.5 million registered direct offering to healthcare-focused institutional investors involving the sale of common stock and warrants.
How much money is GeoVax raising and how will it be used?
The company expects gross proceeds of approximately $2.5 million, which will be used to advance product candidates including research and development, manufacturing, clinical studies, and working capital.
What are the specific terms of the offering?
The offering includes 3,968,256 shares of common stock and warrants to purchase up to 11,904,768 shares at a combined price of $0.63 per share and accompanying warrant, with warrants exercisable at $0.63 per share for 5 years from shareholder approval.
When is the offering expected to close?
The closing is expected to occur on September 30, 2025, subject to customary closing conditions.
Who is managing this offering?
Roth Capital Partners is acting as the sole placement agent for the offering.
What are GeoVax’s main product development programs?
GeoVax’s lead programs include GEO-CM04S1 (a next-generation COVID-19 vaccine in Phase 2 trials), Gedeptin® (an oncolytic solid tumor therapy), and a vaccine targeting Mpox and smallpox that may progress directly to Phase 3 trials.
How can investors obtain more information about this offering?
Electronic copies of the prospectus supplement and accompanying prospectus may be obtained from the SEC’s website at www.sec.gov or by contacting Roth Capital Partners at (800) 678-9147 or 888 San Clemente Drive, Newport Beach CA 92660.
What regulatory framework governs this offering?
The shares are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-277585) previously filed with and declared effective by the SEC on March 13, 2024.
Why is this offering important for GeoVax’s development?
The funding will support the advancement of GeoVax’s clinical-stage programs, including COVID-19 vaccines for immunocompromised patients and cancer therapies, helping move these treatments closer to potential approval and commercialization.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at NewMediaWire
Article Control ID: 239226